210 related articles for article (PubMed ID: 19761936)
1. Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial).
Poulter NR; Dobson JE; Sever PS; Dahlöf B; Wedel H; Campbell NR;
J Am Coll Cardiol; 2009 Sep; 54(13):1154-61. PubMed ID: 19761936
[TBL] [Abstract][Full Text] [Related]
2. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
Sever PS; Poulter NR; Dahlof B; Wedel H;
J Hypertens; 2009 May; 27(5):947-54. PubMed ID: 19318984
[TBL] [Abstract][Full Text] [Related]
3. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients--an Anglo-Scandinavian cardiac outcomes trial substudy.
Dolan E; Stanton AV; Thom S; Caulfield M; Atkins N; McInnes G; Collier D; Dicker P; O'Brien E;
J Hypertens; 2009 Apr; 27(4):876-85. PubMed ID: 19516185
[TBL] [Abstract][Full Text] [Related]
4. Coronary heart disease benefits from blood pressure and lipid-lowering.
Sever PS; Poulter NR; Mastorantonakis S; Chang CL; Dahlof B; Wedel H;
Int J Cardiol; 2009 Jun; 135(2):218-22. PubMed ID: 19232755
[TBL] [Abstract][Full Text] [Related]
5. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Williams B; Lacy PS; Thom SM; Cruickshank K; Stanton A; Collier D; Hughes AD; Thurston H; O'Rourke M; ; ;
Circulation; 2006 Mar; 113(9):1213-25. PubMed ID: 16476843
[TBL] [Abstract][Full Text] [Related]
6. Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial--Blood Pressure Lowering Arm and the relative influence of antihypertensive medication.
Gupta AK; Dahlof B; Dobson J; Sever PS; Wedel H; Poulter NR;
Diabetes Care; 2008 May; 31(5):982-8. PubMed ID: 18235048
[TBL] [Abstract][Full Text] [Related]
7. Impact of amlodipine-based therapy among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA).
Collier DJ; Poulter NR; Dahlöf B; Sever PS; Wedel H; Buch J; Caulfield MJ;
J Hypertens; 2011 Mar; 29(3):583-91. PubMed ID: 21297503
[TBL] [Abstract][Full Text] [Related]
8. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial.
Sever P; Dahlöf B; Poulter N; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen S; Kristinsson A; McInnes G; Mehlsen J; Nieminem M; O'Brien E; Ostergren J;
Eur Heart J; 2006 Dec; 27(24):2982-8. PubMed ID: 17145722
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of antihypertensive treatment on left ventricular diastolic function: an ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) substudy.
Tapp RJ; Sharp A; Stanton AV; O'Brien E; Chaturvedi N; Poulter NR; Sever PS; Thom SA; Hughes AD; Mayet J;
J Am Coll Cardiol; 2010 Apr; 55(17):1875-81. PubMed ID: 20413040
[TBL] [Abstract][Full Text] [Related]
10. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
[TBL] [Abstract][Full Text] [Related]
11. [The most recent study into blood pressure lowering by amlodipine: the beginning of the end for the beta-blockers].
van den Meiracker AH; van Montfrans GA
Ned Tijdschr Geneeskd; 2006 Apr; 150(16):886-8. PubMed ID: 16686086
[TBL] [Abstract][Full Text] [Related]
12. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.
Dahlöf B; Sever PS; Poulter NR; Wedel H; Beevers DG; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J;
Lancet; 2005 Sep 10-16; 366(9489):895-906. PubMed ID: 16154016
[TBL] [Abstract][Full Text] [Related]
13. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial.
Zanchetti A; Julius S; Kjeldsen S; McInnes GT; Hua T; Weber M; Laragh JH; Plat F; Battegay E; Calvo-Vargas C; Cieśliński A; Degaute JP; Holwerda NJ; Kobalava J; Pedersen OL; Rudyatmoko FP; Siamopoulos KC; Störset O
J Hypertens; 2006 Nov; 24(11):2163-8. PubMed ID: 17053536
[TBL] [Abstract][Full Text] [Related]
14. [Prevention of cardiovascular events by the antihypertensive treatment using amlodipine and perindopril in comparison with the use of atenolol and bendroflumethiazide. The ASCOT (Anglo-Scandinavian Outcomes Trail: blood pressure lowering arm) study results--multicentre, randomised, controlled trial. Landmark in the development of opinions on combination therapy in hypertension? (comment)].
Widimský J
Vnitr Lek; 2005 Dec; 51(12):1394-6, 1398-9. PubMed ID: 16430107
[TBL] [Abstract][Full Text] [Related]
15. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
Oparil S; Bakir SE
Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
[TBL] [Abstract][Full Text] [Related]
16. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
Okin PM; Wachtell K; Kjeldsen SE; Julius S; Lindholm LH; Dahlöf B; Hille DA; Nieminen MS; Edelman JM; Devereux RB
Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):337-43. PubMed ID: 19808428
[TBL] [Abstract][Full Text] [Related]
17. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Davis BR; Piller LB; Cutler JA; Furberg C; Dunn K; Franklin S; Goff D; Leenen F; Mohiuddin S; Papademetriou V; Proschan M; Ellsworth A; Golden J; Colon P; Crow R;
Circulation; 2006 May; 113(18):2201-10. PubMed ID: 16651474
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen.
Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B;
Heart; 2008 Feb; 94(2):e4. PubMed ID: 17916665
[TBL] [Abstract][Full Text] [Related]
20. Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial.
Gupta A; Mackay J; Whitehouse A; Godec T; Collier T; Pocock S; Poulter N; Sever P
Lancet; 2018 Sep; 392(10153):1127-1137. PubMed ID: 30158072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]